About asciminib hydrochloride
BCR-ABL1 tyrosine kinase inhibitor
Used for
- Treats Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, after previous treatment.
- Also treats newly diagnosed chronic-phase disease in some countries.
Usual adult dose
Usually 80 mg once daily or 40 mg twice daily; dosing depends on treatment history and local approval.
Common side effects
- Low blood-cell counts
- Pancreatitis or increased pancreatic enzymes
- High blood pressure
- Rash, fatigue, headache, or nausea
Important warnings
- Can cause severe low blood counts; blood tests are needed during treatment.
- Pancreatitis can occur; monitor for abdominal pain and pancreatic enzyme changes.
- May cause cardiovascular problems, high blood pressure, or abnormal heart rhythms.
- Avoid food for at least two hours before and one hour after each dose.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for one week after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for one week after the last dose.
Interactions
- Strong CYP3A4 inhibitors or inducers can change asciminib levels.
- Avoid drugs that prolong the QT interval when possible.
- Acid-reducing medicines may affect absorption; timing adjustments may be needed.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.